Wegovy 7.2 mg: The Higher-Dose Semaglutide Under FDA Review at Roughly 19% Weight Loss

Novo Nordisk has submitted a higher-dose version of Wegovy to the FDA. Semaglutide 7.2 mg once weekly subcutaneous injection, up from the currently-approved 2.4 mg maximum, produced roughly 19% mean weight loss over 68 weeks in the Phase 3 STEP UP trial. That compares to roughly 15% weight loss on the current 2.4 mg dose (STEP-1).

The FDA review is ongoing. Novo Nordisk has not publicly disclosed the target action date, but industry expectations place a possible decision in late 2026 or early 2027. If approved, Wegovy 7.2 mg would give current Wegovy patients an option to intensify their treatment without switching to a different drug class.

The practical question for a current Wegovy user is: is a higher dose of the same drug worth pursuing, or is it worth switching to Zepbound (tirzepatide, roughly 21% weight loss at 15 mg) or waiting for retatrutide (expected 2027-2028, roughly 28.7% weight loss at 12 mg)? This piece walks through the STEP UP data, the FDA review, tolerability at higher doses, and how Wegovy 7.2 mg compares to the competing options.

The short answer: Wegovy 7.2 mg extends the semaglutide franchise into modestly higher efficacy territory without asking patients to change drugs. It does not close the gap with tirzepatide's 21% or retatrutide's 28.7%, but it is a real option for patients who tolerate semaglutide well and want more weight loss from the same drug they know.

STEP UP is the Phase 3 trial that supports the Wegovy 7.2 mg regulatory submission. Understanding the trial design and results is important context for evaluating the drug.

Trial design. STEP UP was a randomized, double-blind trial in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Participants received semaglutide 7.2 mg once weekly, semaglutide 2.4 mg once weekly (the currently-approved dose), or placebo, all alongside a lifestyle intervention. Duration: 68 weeks. Enrolment was in the 1,000-plus range.

Primary results. Semaglutide 7.2 mg delivered roughly 19% mean weight loss at 68 weeks, compared to roughly 15% for the 2.4 mg group and roughly 3-4% for placebo. The 4 percentage point improvement of 7.2 mg over 2.4 mg represents an incremental efficacy step that is smaller than the 5-6 point jump from 2.4 mg semaglutide to 15 mg tirzepatide but is a real and statistically significant gain.

Responder proportions. The share of patients achieving 20% or greater weight loss increased substantially at 7.2 mg versus 2.4 mg. At 2.4 mg, roughly 32% of STEP-1 participants achieved 20% or greater weight loss. At 7.2 mg in STEP UP, that fraction climbed to roughly 45-50%, moving the drug closer to tirzepatide territory on the responder curve.

Safety profile. GI side effects (nausea, vomiting, constipation, diarrhea) increased in frequency at 7.2 mg versus 2.4 mg, as expected for a dose-dependent side-effect profile. Discontinuation rates due to GI intolerance at 7.2 mg were somewhat higher than at 2.4 mg. The drug remained generally well-tolerated with no new safety signals beyond what has been documented for semaglutide across the STEP program.

Efficacy at three doses. The three semaglutide doses now characterized in weight-loss trials (2.4 mg → 15%, and the two intermediate steps 1.7 mg and 4.8 mg tested in adjacent studies → intermediate results, and 7.2 mg → 19%) show that the drug's dose-response continues to climb beyond 2.4 mg but with diminishing returns per additional milligram. The 2.4-to-7.2 mg step tripled the dose for a 4 percentage point efficacy gain.

Novo Nordisk submitted the Wegovy 7.2 mg supplemental new drug application to the FDA earlier in 2026. Novo Nordisk has not publicly disclosed the target action date under the Prescription Drug User Fee Act (PDUFA), so the exact timing of a potential approval is not on public record.

Standard versus priority review. A supplemental new drug application (sNDA) for a new dose of an already-approved drug typically qualifies for standard review (10 months from submission acceptance). Priority review (6 months) is possible for applications that address a substantially unmet need, but higher-dose semaglutide is unlikely to qualify for that framing given the availability of other higher-efficacy options.

Expected timing. If the sNDA was accepted by the FDA in Q1 2026, standard review would produce a decision in Q4 2026 or early 2027. If it was accepted later in 2026, the decision would land in the first half of 2027.

What could go wrong. The review could produce a Complete Response Letter (CRL) if the FDA identifies safety concerns not adequately addressed in the sNDA package, or if manufacturing / chemistry / controls issues arise. Semaglutide is a well-characterized peptide manufactured at commercial scale by Novo Nordisk, and the safety database at 2.4 mg is very large, so major surprises are unlikely. But delays for procedural reasons (label negotiations, additional analyses) are always possible.

Commercial launch preparation. Novo Nordisk has not publicly detailed the launch strategy for Wegovy 7.2 mg. Likely commercial factors: a modest premium over the 2.4 mg price (currently roughly $1,349/month WAC), same delivery device (once-weekly subcutaneous injection pen), and marketing focused on current Wegovy patients who tolerate the drug well but want more weight loss.

GLP-1 receptor agonists have well-characterized GI side effects that increase with dose. STEP UP data plus the broader semaglutide safety database suggest what higher-dose users can expect.

Nausea. The most common side effect on semaglutide. At 2.4 mg, roughly 40% of STEP-1 participants reported nausea, mostly mild-to-moderate and most common during the titration phase. At 7.2 mg, nausea rates likely climb to roughly 50-55%, with slightly higher severity distribution.

Vomiting. Roughly 20% at 2.4 mg. Likely 25-30% at 7.2 mg.

Constipation and diarrhea. Both dose-dependent. Constipation is often more persistent than nausea, which typically diminishes over the first several months. Constipation can require ongoing management with fiber, hydration, and stool softeners.

Injection-site reactions. Not dose-dependent in the same way as GI effects. Similar frequency at 7.2 mg versus 2.4 mg.

Discontinuation due to side effects. Roughly 5-7% of STEP-1 participants discontinued for adverse events at 2.4 mg. At 7.2 mg, discontinuation rates were somewhat higher, in the 8-10% range based on trial data.

Titration strategy. Wegovy 7.2 mg will presumably use an extended dose-escalation schedule similar to the current Wegovy titration (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16-20 weeks). Adding two more titration steps (2.4 → 4.8 → 7.2 mg) would extend the escalation period to roughly 24-32 weeks. Patients should plan for a longer titration path if the FDA-approved schedule follows the trial protocol.

Reversibility. Side effects on semaglutide are generally reversible after dose reduction or discontinuation. Patients who cannot tolerate 7.2 mg can typically return to 2.4 mg or a lower maintenance dose without long-term consequences.

The most important comparative question for a current Wegovy patient thinking about Wegovy 7.2 mg is: how does it stack up against the switch to Zepbound (tirzepatide)?

Efficacy. Zepbound 15 mg produced roughly 21% weight loss at 72 weeks in SURMOUNT-1. Wegovy 7.2 mg produced roughly 19% at 68 weeks in STEP UP. The 2 percentage point gap is real but small, and individual response variability easily exceeds it. There is no head-to-head trial of Wegovy 7.2 mg versus Zepbound 15 mg.

Mechanism. Wegovy 7.2 mg is more semaglutide (GLP-1 receptor agonist). Zepbound is a different molecule (GIP + GLP-1 dual agonist). Patients who tolerate semaglutide well but wonder if tirzepatide's dual mechanism would produce more weight loss for them individually have no way to know without trying it.

Delivery device. Both are once-weekly subcutaneous injection pens. Familiar territory for current Wegovy users. No substantial convenience difference.

Cost and insurance. Wegovy and Zepbound are similar list prices (roughly $1,000-$1,350/month WAC depending on which one and which pharmacy). Insurance coverage for GLP-1 obesity drugs varies substantially by plan; some plans cover one but not the other. A prescriber can help determine which is covered under a specific patient's plan.

Side effect profile. Both drugs have GI side effects. Some patients report tirzepatide is somewhat better tolerated for nausea than semaglutide, potentially because the GIP component blunts GLP-1-induced nausea. This is anecdotal and not conclusive. Individual tolerability varies.

Switching considerations. Patients switching from Wegovy to Zepbound typically start at the lowest Zepbound dose (2.5 mg) and titrate up, even if they were at the highest Wegovy dose. Switching is not trivial: it involves a new titration period, potentially another wave of nausea, and no guarantee that the new drug will work better for that individual patient.

Practical framing. Wegovy 7.2 mg is the low-friction intensification path. Zepbound is the switch to a potentially higher-efficacy drug with more uncertainty. For patients who tolerate semaglutide well and have a stable Wegovy supply, Wegovy 7.2 mg is likely the simpler choice. For patients who are hitting a plateau at 2.4 mg with substantial residual weight loss goals and are willing to go through a new titration, Zepbound is worth discussing with a prescriber.

The other question a Wegovy patient might have is: should I wait for retatrutide instead? The answer is usually no, but understanding why is important.

Retatrutide's efficacy. Once-weekly injectable GIP/GLP-1/glucagon triple agonist. Roughly 28.7% weight loss at 68 weeks at the 12 mg dose in Phase 3 TRIUMPH-1. Highest weight-loss magnitude of any obesity drug in Phase 3 to date.

Retatrutide's timeline. Eli Lilly plans to submit the BLA to the FDA in Q1 2027. Standard 10-month review would place a potential approval decision in Q4 2027 or Q1 2028. Priority review (if a Priority Review Voucher is deployed) could compress that to Q3 2027. After approval, insurance coverage and formulary access typically take another 6-12 months. Realistic prescribing availability is late 2027 or early 2028.

The wait math. A patient starting Wegovy 7.2 mg in Q1 2027 (assuming approval by then) could achieve 19% weight loss by Q1-Q2 2028. A patient waiting for retatrutide instead would likely be starting the drug in Q3 2027 or later and reaching similar or higher weight loss by mid-to-late 2028. The wait cost is real: 6-12 months of not losing weight, with potential health consequences depending on the patient's baseline BMI and comorbidities.

Insurance and cost. Retatrutide is likely to launch at a premium price to current Wegovy/Zepbound levels, given its efficacy leadership. Initial insurance coverage will be limited to patients with the highest BMI and most severe comorbidities. Broad access may take another 1-2 years after approval.

Practical framing. Waiting for retatrutide makes sense for patients who have not yet started any GLP-1 therapy, do not have urgent weight-related health concerns, and are prepared to pay premium prices out-of-pocket. For current Wegovy patients tolerating the drug well and wanting more weight loss, intensifying to Wegovy 7.2 mg (or switching to Zepbound) now generally produces better real-world outcomes than waiting.

For current Wegovy 2.4 mg patients thinking about the higher-dose option (once approved), a few criteria help identify who is likely to benefit.

Good candidates:

• Currently at Wegovy 2.4 mg for at least 6 months with acceptable tolerability (mild-to-moderate GI side effects that have stabilized)
• Have achieved less weight loss than expected (below 10% at 6-12 months) with consistent adherence
• Have residual weight loss goals of 15-30 pounds or more
• Reliable insurance coverage or ability to pay the modest premium for the higher dose
• Access to a prescriber who will titrate through the extended dose escalation carefully

Marginal candidates:

• Already achieving good weight loss on 2.4 mg (15%+); the marginal benefit of going to 7.2 mg may not be worth the increased side-effect burden
• Struggling with GI side effects at 2.4 mg; higher dose will likely worsen the side-effect profile
• Considering discontinuation soon regardless; intensification does not solve the maintenance-and-regain problem

Not typically good candidates:

• Patients who have consistently regained weight when trying to titrate up in the past
• Patients with prior severe pancreatitis, medullary thyroid carcinoma family history, or MEN 2 (contraindications for semaglutide generally)
• Patients who cannot maintain consistent weekly dosing (dose gaps blunt the effect of any dose)

A specific practical point. If Wegovy 7.2 mg is approved and prescribed for a patient who has been at 2.4 mg for extended periods, the titration will likely restart at intermediate steps (2.4 → 4.8 → 7.2 mg) rather than dropping back to 0.25 mg. That means the escalation period is likely to be 8-12 weeks rather than the 16-20 weeks for a Wegovy-naive patient. GI side effects should be expected during each dose step up.

Wegovy 7.2 mg is a higher-dose version of Novo Nordisk's semaglutide 2.4 mg product, currently under FDA review with an expected approval decision in late 2026 or early 2027. Phase 3 STEP UP results showed roughly 19% mean weight loss at 68 weeks, versus roughly 15% for the 2.4 mg dose. That extends the semaglutide franchise into modestly higher efficacy territory without asking patients to change drug classes.

Compared to Zepbound (tirzepatide 15 mg, roughly 21% weight loss at 72 weeks), Wegovy 7.2 mg lags by roughly 2 percentage points but offers the continuity of staying on the same drug the patient already tolerates. Compared to retatrutide (roughly 28.7% at 68 weeks, expected approval 2027-2028), Wegovy 7.2 mg is available sooner but at meaningfully lower efficacy.

For current Wegovy patients who tolerate semaglutide well and have residual weight-loss goals, Wegovy 7.2 mg will likely be the simpler intensification path once approved. GI side effects will increase modestly at the higher dose; discontinuation rates from adverse events run at roughly 8-10% versus 5-7% for the current dose. Titration from 2.4 mg to 7.2 mg will add several months to the ramp-up before reaching the maintenance dose.

For patients starting GLP-1 therapy today, the choice is more complex. Semaglutide 2.4 mg (Wegovy or Ozempic) at 15%, tirzepatide 15 mg (Zepbound or Mounjaro) at 21%, and retatrutide (in 2027-2028) at 28.7% are the currently-available and near-term efficacy tiers. Wegovy 7.2 mg at 19% will sit between the current tirzepatide tier and the current semaglutide tier when it launches. Individual response, tolerability, insurance coverage, and preferences determine which tier makes sense for which patient, and that conversation belongs with a prescriber.